RecruitingNCT06597539
The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
A Prospective Study on Investigating the Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
Sponsor
Ruijin Hospital
Enrollment
40 participants
Start Date
Nov 9, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced hepatobiliary malignancies.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria5
- Pathological and clinical diagnosis of advanced hepatobiliary malignancy requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines
- Signed and dated informed consent form
- Commitment to comply with research procedures and co-operation in the implementation of the full research process
- aged 18-75 years old
- The patient is in good general condition with an expected survival of \> 6 months
Exclusion Criteria5
- Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc.
- Intestinal perforation, complete intestinal obstruction
- Uncontrolled diabetes patients or fasting blood glucose levels ≥11 mmol/L on the day of the trial
- Pregnant women and women who may be pregnant, women who are breastfeeding.
- Non-compliant person
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06597539